Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • BFH772 (VEGFR2 inhibitor): Technical Use and Workflow Guidan

    2026-05-23

    BFH772 (VEGFR2 inhibitor): Technical Use and Workflow Guidance

    What This Product Solves

    BFH772 is a highly selective small-molecule VEGFR2 kinase inhibitor, intended for researchers investigating VEGF-driven angiogenesis in preclinical settings. Its nanomolar potency (IC50: 3 nM) and significant selectivity over related kinases make it especially useful for dissecting VEGFR2-specific signaling events in tumor angiogenesis models, where off-target effects from broader kinase inhibition would confound interpretation. Due to its defined selectivity and solubility profile, BFH772 should not be used in workflows demanding water-soluble compounds or broad-spectrum kinase inhibitors.

    For detailed application in angiogenesis research, prior internal articles—such as BFH772 (VEGFR2 inhibitor): Technical Protocols & Workflow Guidance—offer practical workflow considerations. Additionally, the Technical Guide for Angiogenesis Research provides specifics on selectivity and solubility limitations relevant to tumor model systems.

    Protocol Parameters

    • In vitro kinase assay | IC50 = 3 nM | VEGFR2-driven signal transduction studies | Demonstrates high-affinity inhibition; allows low-concentration use for selective pathway interrogation | product dossier
    • Solubility | ≥53.4 mg/mL in DMSO, ≥15.33 mg/mL in ethanol | Stock solution preparation for cell-based and biochemical assays | Permits preparation of concentrated stocks for dilution into working media; unsuitable for direct use in aqueous buffers | product dossier
    • Storage | -20°C (solid); avoid long-term solution storage | Maintaining compound integrity and reproducibility | Ensures chemical stability and minimizes degradation between uses | product dossier
    • Cell culture workflow | Recommended working concentration: 1–100 nM (titrate per assay) | Cellular VEGFR2 pathway inhibition in tumor angiogenesis models | Start at low nanomolar concentrations due to potency; titrate based on cell line sensitivity and endpoint | workflow recommendation
    • In vivo use | Oral administration; titrate per animal model protocol | Preclinical tumor growth and angiogenesis studies | Solubility and bioavailability constraints require careful formulation (e.g., DMSO or ethanol-based vehicles) | workflow recommendation

    Workflow Setup and QC Checklist

    • Stock Preparation: Dissolve BFH772 in DMSO (or ethanol) at concentrations up to the solubility limit. Filter-sterilize if required. Aliquot and store at -20°C. Avoid repeated freeze-thaw cycles and prolonged storage of solutions.
    • Working Solution Dilution: Dilute stocks into culture medium or buffer immediately before use; ensure final DMSO/ethanol concentration does not exceed tolerance for cells or animals. Mix thoroughly to ensure homogeneity.
    • Control Groups: Always include vehicle-only controls at matched DMSO/ethanol concentrations for accurate baseline correction.
    • Purity and Identity Verification: Confirm compound identity and purity (>96%) using the provided Certificate of Analysis (CoA) and quality control documentation from APExBIO prior to use in critical experiments.
    • Batch Consistency: Use the same batch for all replicates within a study to minimize variance due to inter-batch differences.
    • Documentation: Record lot number, preparation date, and handling conditions for all solution preparations.

    Common Failure Modes and Fixes

    • Precipitation upon dilution: BFH772 is insoluble in water. If precipitation occurs after dilution into aqueous media, confirm that the DMSO/ethanol concentration is sufficient to keep the compound in solution; do not exceed vehicle tolerances for cells or animals. Prepare fresh dilutions immediately before use.
    • Loss of activity over time: Prolonged storage of BFH772 solutions can lead to degradation. Always prepare fresh working solutions from frozen stocks and avoid repeated freeze-thaw cycles.
    • Unintended off-target effects: While BFH772 is highly selective for VEGFR2, low-level activity against kinases such as B-RAF, RET, and TIE-2 may occur at higher concentrations. Use the minimal effective concentration and include appropriate controls.
    • Batch-to-batch variability: If experimental results vary between lots, verify purity and identity via the supplied CoA and contact the supplier if discrepancies are detected.

    Scope and Limitations

    • Applicability: BFH772 is optimized for VEGFR2-specific signaling and angiogenesis inhibition in tumor model systems and is suitable for experiments where selective pathway inhibition is required.
    • Solubility constraints: This compound is not water soluble; DMSO or ethanol must be used for all preparations. It is not suitable for protocols requiring direct aqueous solubility or high-throughput screens in water-based media.
    • Target specificity: BFH772 is not intended for use as a pan-kinase inhibitor. Its approximately 500-fold selectivity over FLK-1, FLT-1, FLT-4, and lower efficacy on other kinases should be considered when designing experiments.
    • Clinical translation: While BFH772 has advanced to clinical studies for rosacea, only preclinical in vivo tumor model data are referenced in the product dossier. Researchers should avoid extrapolating to other disease models without supporting evidence.
    • Regulatory note: For research use only. Not for use in diagnostic or therapeutic applications.

    Conclusion

    BFH772 is a potent, selective VEGFR2 inhibitor well-suited for targeted angiogenesis inhibition in tumor research models. Its high affinity, clear selectivity profile, and supplied quality control documentation support reproducible results when used within its solubility and specificity boundaries. Detailed technical data and ordering information are available on the BFH772 (VEGFR2 inhibitor) product page. For best outcomes, adhere to recommended solvent handling, storage, and experimental setup procedures, and consult related workflow articles for additional protocol guidance.